ReviewAutoimmune diseases2014
An update in guillain-barré syndrome.
Review in Autoimmune diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.Human vaccines & immunotherapeutics · 2015Pooled it
- Review
- Prevalence and Clinical Associations of A-Waves in Routine Nerve Conduction Studies: A Retrospective Analysis.Noro psikiyatri arsivi · 2026Article
- Article
- Guillain-Barré Syndrome Induced by Vaccination Against COVID-19: A Systematic Review and Meta-Analysis.Cureus · 2023Review
- Rare Organism Uncommon Disease Case Vignette of Guillain-Barré Syndrome Induced byCase reports in infectious diseases · 2021Article
- Are Repeated Cycles of Intravenous Immunoglobulin Justified in Patients With Poorly Responsive Guillain-Barré Syndrome?The Neurohospitalist · 2020Article
- Instrumented Microphysiological Systems for Real-Time Measurement and Manipulation of Cellular Electrochemical Processes.iScience · 2019Review
- Guillain-Barré Syndrome and Its Variants: Clinical Course and Prognostic Factors.Noro psikiyatri arsivi · 2019Article
- A Co-Occurrence of Serologically Proven Myasthenia Gravis and Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome.Case reports in neurological medicine · 2019Article
- Article
- Guillain-Barré syndrome in a Child with Ongoing Viral Hepatitis A.Iranian journal of child neurology · 2018Article
- Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barré syndrome.Oncotarget · 2016Article
- Clinical importance of F-waves as a prognostic factor in Guillain-Barré syndrome in children.Korean journal of pediatrics · 2016Article
- ZIKA--How fast does this virus mutate?Dong wu xue yan jiu = Zoological research · 2016Article
- Enhanced Immune Response in Immunodeficient Mice Improves Peripheral Nerve Regeneration Following Axotomy.Frontiers in cellular neuroscience · 2016Article
- Applying complement therapeutics to rare diseases.Clinical immunology (Orlando, Fla.) · 2015Review
- Mechanisms of distal axonal degeneration in peripheral neuropathies.Neuroscience letters · 2015Review
- A hepatic cancer patient with Guillain-Barré syndrome during the perioperative period of partial hepatectomy: a case report.International journal of clinical and experimental medicine · 2015Article
- Myelin ultrastructure of sciatic nerve in rat experimental autoimmune neuritis model and its correlation with associated protein expression.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) was first described in 1916 (Guillain G, 1916) and is approaching its 100th anniversary. Our knowledge of the syndrome has hugely expanded since that time. Once originally considered to be only demyelinating in pathology we now recognise both axonal and demyelinating subtypes. Numerous triggering or antecedent events including infections are recognised and GBS is considered an immunological response to these. GBS is now considered to be a clinical syndrome of an acute inflammatory neuropathy encompassing a number of subtypes with evidence of different immunological mechanisms. Some of these are clearly understood while others remain to be fully elucidated. Complement fixing antibodies against peripheral nerve gangliosides alone and in combination are increasingly recognised as an important mechanism of nerve damage. New antibodies against other nerve antigens such as neurofascin have been recently described. Research databases have been set up to look at factors associated with prognosis and the influence of intravenous immunoglobulin (IvIg) pharmacokinetics in therapy. Exciting new studies are in progress to examine a possible role for complement inhibition in the treatment of the syndrome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.